Literature DB >> 2188852

Risk of AIDS in HIV seroconverters: a comparison between intravenous drug users and homosexual males.

G Rezza1, A Lazzarin, G Angarano, R Zerboni, A Sinicco, B Salassa, R Pristerà, M Barbanera, L Ortona, F Aiuti.   

Abstract

A multicentre cohort study was conducted in Italy to estimate the risk of developing AIDS in 261 intravenous drug users and 89 homosexual males for whom the seroconversion period was known. Four years after HIV seroconversion, AIDS incidence, estimated by Kaplan-Meier survival technique, was 13.8% for intravenous drug users and 16.2% for homosexual males; the difference was not statistically significant. These findings suggest that four years after seroconversion the risk of developing AIDS in HIV seropositive intravenous drug users is no higher than that of subjects who acquired HIV infection through sexual contact.

Entities:  

Mesh：

Year:  1990        PMID： 2188852     DOI： 10.1007/bf00155560

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN： 0393-2990            Impact factor:   8.082


  4 in total

1.  The natural history of HIV infection in intravenous drug users: risk of disease progression in a cohort of seroconverters.

Authors:  G Rezza; A Lazzarin; G Angarano; A Sinicco; R Pristerà; L Ortona; M Barbanera; S Gafà; U Tirelli; B Salassa
Journal:  AIDS       Date:  1989-02       Impact factor: 4.177

2.  Development of AIDS, HIV seroconversion, and potential co-factors for T4 cell loss in a cohort of intravenous drug users.

Authors:  D C Des Jarlais; S R Friedman; M Marmor; H Cohen; D Mildvan; S Yancovitz; U Mathur; W el-Sadr; T J Spira; J Garber
Journal:  AIDS       Date:  1987-07       Impact factor: 4.177

3.  Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes.

Authors:  J Wybran; T Appelboom; J P Famaey; A Govaerts
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

4.  Incidence of symptoms and AIDS in 146 Swedish haemophiliacs and blood transfusion recipients infected with human immunodeficiency virus.

Authors:  J Giesecke; G Scalia-Tomba; O Berglund; E Berntorp; S Schulman; L Stigendal
Journal:  BMJ       Date:  1988-07-09
  4 in total
  4 in total

1.  Improving the prognostic value of CD4+ count using IgA and clinical signs in HIV-seropositive i.v. drug users.

Authors:  F Montella; P Pezzotti; F Di Sora; O Recchia; F Lauria; G Rezza
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

2.  Serum IgG antibodies to human herpesvirus-6 (HHV-6) do not predict the progression of HIV disease to AIDS. Italian Seroconversion Study group.

Authors:  M Dorrucci; G Rezza; M Andreoni; P Pezzotti; E Nicastri; L Ventura; M Zignani; M B Alliegro; G Tarantini; B Salassa; V Colangeli; G Mazzarello; M A Ursitti; M Barbanera; R Pristerà; F Castelli; L Ortona
Journal:  Eur J Epidemiol       Date:  1999-04       Impact factor: 8.082

3.  Absence of antibodies to human herpesvirus-6 in patients with slowly-progressive human immunodeficiency virus type 1 infection.

Authors:  H Chen; A M Pesce; M Carbonari; F Ensoli; M Cherchi; G Campitelli; D Sbarigia; G Luzi; F Aiuti; M Fiorilli
Journal:  Eur J Epidemiol       Date:  1992-03       Impact factor: 8.082

4.  HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study.

Authors:  A Cozzi Lepri; P Pezzotti; M Dorrucci; A N Phillips; G Rezza
Journal:  BMJ       Date:  1994-12-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.